Catalog name Description price
R-XASYS-00727 Avatrombopag,cas:570406-98-3 Avatrombopag (C29H34Cl2N6O3S2,649.7) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A. price>
R-XASYS-00728 AVE 0991 sodium salt,cas:306288-04-0 AVE 0991 sodium salt(C29H31N4NaO5S2,602.70) is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21 nM. price>
R-XASYS-00729 AVE-3085,cas:450348-85-3 AVE3085(C17H13F2NO3,317.29) is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment. price>
R-XASYS-00730 AVN-492,cas:1220646-23-0 AVN-492(C17H21N5O2S,359.4) is an antagonist of the serotonin (5-HT) receptor subtype 5-HT6 (Ki = 0.09 nM). It selectively inhibits the 5-HT6 receptor over the 5-HT2B receptor (IC50s = 0.19 and 268 nM, respectively, in a radioligand binding assay). AVN-492 inhibits increases in cAMP levels induced by 5-HT in HEK293 cells expressing the 5-HT6 receptor (IC50 = 1.5 nM). price>
R-XASYS-00731 AVX 13616,cas:900814-48-4 AVX 13616(C50H73Cl2N7O7,955.06) shows the potent in vivo antibacterial activity of Avexas lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. price>
R-XASYS-00732 AX-024 hydrochloride,cas:1704801-24-0 AX-024 hydrochloride(C21H23ClFNO2,375.86) is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. price>
R-XASYS-00733 AX-15836,cas:2035509-96-5 AX-15836(C32H40N8O5S,648.78) is a potent and selective ERK5 inhibitor with an IC50 of 8 nM. price>
R-XASYS-00734 AZ PFKFB3 26,cas:1704740-52-2 AZ PFKFB3 26(C24H26N4O2,402.49) is a potent and selective inhibitor of the metabolic kinase PFKFB3 with an IC50 of 23 nM. AZ PFKFB3 26 inhibits PFKFB1 and PFKFB2 with IC50s of 2.06 and 0.384 μM, respectively. price>
R-XASYS-00735 AZ-1355,cas:75451-07-9 AZ-1355(C17H17NO4,299.32) is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro. price>
R-XASYS-00736 AZ12672857,cas:945396-55-4 AZ12672857(C26H30N8O2,486.57) is an orally active inhibitor of EphB4 (IC50=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC50=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM). price>